Rakesh K. Jain to present on cutting-edge tumor treatment
On September 24, Rakesh Jain, Ph.D. of the Harvard Medical School and Massachusetts General Hospital will present a lecture entitled: Taming Tumor Vessels for Cancer Treatment: From Bench to Bedside and Back.
The program is a part of the annual William E. Schiesser Lecture Series and the 2008 Chemical Engineering Fall Seminar Series. Jain explains that because blood vessels in tumors are abnormal in structure and function, treatments do not sufficiently attack and destroy the cancerous cells. He proposes that if the tumor vessels can be “normalized,” then the cancer could be treated more effectively.
Ironically, treatments designed to destroy tumor vessels can also repair them. These same drugs are now more capable of attacking and destroying the newly altered cells. A similar application is also being tested in other vascular disorders such as macular degeneration.
Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School, and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital. Himself a chemical engineer, he has also served as assistant professor of chemical engineering at Columbia and as a full professor of chemical engineering at Carnegie Mellon University.
Jain has written more than 435 publications and serves on advisory panels to the government and industry and 10 editorial boards for scientific journals. He has received 30 major awards including a Guggenheim Fellowship, and Outstanding Investigator Grant, and the Academic Scientist of the Year Award from the Pharmaceutical Achievements Awards.
The lecture will take place on Wednesday, Sept. 24 at 2:30 p.m. in Room B023 in Iacocca Hall with a light reception beginning at 2:15 p.m.
Christine Rapp
| Rakesh Jain |
The program is a part of the annual William E. Schiesser Lecture Series and the 2008 Chemical Engineering Fall Seminar Series. Jain explains that because blood vessels in tumors are abnormal in structure and function, treatments do not sufficiently attack and destroy the cancerous cells. He proposes that if the tumor vessels can be “normalized,” then the cancer could be treated more effectively.
Ironically, treatments designed to destroy tumor vessels can also repair them. These same drugs are now more capable of attacking and destroying the newly altered cells. A similar application is also being tested in other vascular disorders such as macular degeneration.
Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School, and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital. Himself a chemical engineer, he has also served as assistant professor of chemical engineering at Columbia and as a full professor of chemical engineering at Carnegie Mellon University.
Jain has written more than 435 publications and serves on advisory panels to the government and industry and 10 editorial boards for scientific journals. He has received 30 major awards including a Guggenheim Fellowship, and Outstanding Investigator Grant, and the Academic Scientist of the Year Award from the Pharmaceutical Achievements Awards.
The lecture will take place on Wednesday, Sept. 24 at 2:30 p.m. in Room B023 in Iacocca Hall with a light reception beginning at 2:15 p.m.
Christine Rapp
Posted on:
Thursday, September 18, 2008
Share This Story:
